Curis (NASDAQ:CRIS) Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Curis (NASDAQ:CRIS) to a strong sell rating in a report issued on Saturday morning.

A number of other analysts have also recently commented on CRIS. HC Wainwright reaffirmed a “buy” rating and set a $43.00 price target (up from $17.00) on shares of Curis in a research report on Friday, July 24th. Zacks Research raised Curis from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Curis presently has a consensus rating of “Hold” and an average price target of $43.00.

Curis Stock Performance

NASDAQ:CRIS opened at $3.66 on Friday. The firm’s fifty day moving average is $6.48 and its 200-day moving average is $12.15. Curis has a 52 week low of $3.50 and a 52 week high of $39.00. The firm has a market cap of $7.14 million, a P/E ratio of -0.15 and a beta of 3.13.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share for the quarter, missing the consensus estimate of ($6.53) by ($18.47). As a group, sell-side analysts anticipate that Curis will post -33.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CRIS. Squarepoint Ops LLC grew its stake in shares of Curis by 17.9% in the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 8,973 shares during the period. Jane Street Group LLC increased its position in Curis by 71.8% in the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 10,586 shares in the last quarter. XTX Topco Ltd acquired a new position in Curis during the 4th quarter worth approximately $26,000. Maverick Capital Ltd. raised its stake in Curis by 7.8% during the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after buying an additional 49,554 shares during the period. Finally, Focused Wealth Management Inc boosted its holdings in Curis by 83.4% in the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 49,900 shares in the last quarter. 29.97% of the stock is owned by institutional investors.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.